IL6 and COVID-19: In a double-blind, randomized, and controlled COVID-19 clinical trial, patients treated intravenously (IV) with 2 doses of umbilical cord derived-MSC on days 0 and 3 showed significant reductions in the concentrations of pro-inflammatory IFNγ, IL-5, IL-6, IL-7, TNFα, and TNFß at a single time-point 6 days after treatment by comparison to the day prior to treatment.13 This suppression of cytokine storm was accompanied by significantly improved survival (91% with MSC treatment vs. 42% in the control group).